Mesothelin antibody (MSLN) (Extracellular Domain)

Details for Product anti-MSLN Antibody No. ABIN964689
Antigen
  • MPF
  • SMRP
  • MSLN
  • mesothelin
  • MSLN
  • Msln
  • LOC611363
  • LOC100524016
Epitope
Extracellular Domain
16
10
7
7
5
4
4
4
4
4
4
4
4
4
3
3
3
2
2
2
1
1
1
1
1
1
1
1
Reactivity
Human
149
32
9
2
2
2
2
1
1
1
Host
Mouse
116
41
7
4
1
Clonality (Clone)
Monoclonal ()
Conjugate
This Mesothelin antibody is un-conjugated
15
9
9
3
3
3
3
3
3
2
1
1
1
1
1
1
1
Application
Immunohistochemistry (IHC), Western Blotting (WB)
102
68
40
21
19
13
8
7
6
6
4
4
3
2
2
2
2
1
Options
Immunogen This antibody was produced in mice by repeated immunizations with a recombinant protein corresponding to the of human mesothelin.
Immunogentype:Recombinant
Clone MN-1
Isotype IgG
Characteristics Concentration Definition: by UV absorbance at 280 nm
Plasmids, Primers & others Plasmids, Primers & others Mesothelin products on genomics-online (e.g. as negative or positive controls)
Antigen
Alternative Name Mesothelin (MSLN Antibody Abstract)
Background Anti Mesothelin Antibody recognizes Mesothelin that is a glycosyl-phosphatidylinositol–anchored glycoprotein present on the cell surface of various human solid tumors.  The mesothelin (MSLN) gene encodes a 71-kDa precursor protein that is processed to a 40-kDa glycosylphosphatidylinositol–anchored protein that composes the mature portion and an NH2 terminal 31-kDa fragment called megakaryocyte-potentiating factor that is released from the cell.  Mesothelin is a tumor differentiation antigen present at low levels on a restricted set of normal adult tissues, such as mesothelium, but aberrantly over expressed in mesotheliomas, ovarian, and pancreatic cancers.  The biological functions of mesothelin remain elusive.  A recent study showed that mesothelin binds to MUC16/CA125, and that this interaction mediates cell adhesion, suggesting that there may be an important role for MUC16/CA125 and mesothelin in the metastatic spread of ovarian cancer.
Synonyms: Mesothelian, MN, MB, Pre-pro-megakaryocyte-potentiating factor, CAK1 antigen
Gene ID 10232
NCBI Accession NP_005814
UniProt Q13421
Pathways EGFR Signaling Pathway, Positive Regulation of Peptide Hormone Secretion, Intracellular Steroid Hormone Receptor Signaling Pathway, Steroid Hormone Mediated Signaling Pathway, Carbohydrate Homeostasis, cAMP Metabolic Process, Regulation of G-Protein Coupled Receptor Protein Signaling, Positive Regulation of Endopeptidase Activity, Regulation of Carbohydrate Metabolic Process
Application Notes This antibody has been tested for use in immunohistochemistry and western blotting. Specific conditions for reactivity should be optimized by the end user. Expect a band approximately 40 kDa in size corresponding to mature mesothelin by western blotting in the appropriate cell lysate or extract. For immunohistochemistry, archival PEFF human tissues were deparaffinized followed by hydration.  Antigen-retrieval is recommended.  Block tissues with 1% BSA in PBS for 30 min at 23° C.  Antibodies are diluted in 1% BSA and reacted with tissue for 60 min at room temperature.
Restrictions For Research Use only
Format Liquid
Concentration 1.0 mg/mL
Buffer 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage -20 °C
Supplier Images
Image no. 1 for anti-Mesothelin (MSLN) (Extracellular Domain) antibody (ABIN964689) Immunohistochemistry using anti-mesothelin antibodies to detect mesothelin in PEFF h...
Image no. 2 for anti-Mesothelin (MSLN) (Extracellular Domain) antibody (ABIN964689) Western blotting using anti-mesothelin antibodies to detect mesothelin-Fc at 100 ng ...
Product cited in: Zhang, Khanna, Jiang, Alewine, Miettinen, Pastan, Hassan: "Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 23, Issue 6, pp. 1564-1574, 2018 (PubMed).

Oehl, Kresoja-Rakic, Opitz, Vrugt, Weder, Stahel, Wild, Felley-Bosco: "Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression." in: Frontiers in oncology, Vol. 8, pp. 40, 2018 (PubMed).

Khanna, Thomas, Abate-Daga, Zhang, Morrow, Steinberg, Orlandi, Ferroni, Schlom, Guadagni, Hassan: "Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab." in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Vol. 11, Issue 11, pp. 1993-2005, 2017 (PubMed).

Awuah, Bera, Folivi, Chertov, Pastan: "Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins." in: Molecular cancer therapeutics, Vol. 15, Issue 7, pp. 1648-55, 2017 (PubMed).

Xiang, Phung, Feng, Nagashima, Zhang, Broaddus, Hassan, Fitzgerald, Ho: "The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy." in: PLoS ONE, Vol. 6, Issue 1, pp. e14640, 2011 (PubMed).

Feng, Zhang, Anver, Hassan, Ho: "In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice." in: Journal of Cancer, Vol. 2, pp. 123-31, 2011 (PubMed).

Ho, Bera, Willingham, Onda, Hassan, FitzGerald, Pastan: "Mesothelin expression in human lung cancer." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 13, Issue 5, pp. 1571-5, 2007 (PubMed).

Onda, Willingham, Nagata, Bera, Beers, Ho, Hassan, Kreitman, Pastan: "New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 11, Issue 16, pp. 5840-6, 2005 (PubMed).

Did you look for something else?